Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock's performance in the coming months [6]. Core Insights - The company, Sheng Bella, is expected to achieve a revenue of no less than 1.035 billion yuan in 2025, representing a year-on-year growth of at least 30%. The adjusted net profit is projected to be no less than 120 million yuan, reflecting a significant increase of 183% [1]. - The company is actively expanding its store network, with a total of 113 stores as of the first half of 2025, an increase of 36 stores compared to the end of 2024. This expansion is expected to enhance customer recognition and improve data richness for AI applications [2]. - The management's confidence in the company's growth is demonstrated through a share incentive plan and stock purchases by the chairman, indicating a commitment to long-term value creation [3]. Financial Projections - Revenue projections for 2025-2027 are as follows: 1.0365 billion yuan in 2025, 1.302 billion yuan in 2026, and 1.601 billion yuan in 2027, with corresponding adjusted net profits of 119 million yuan, 232 million yuan, and 288 million yuan respectively [4][5]. - The company is expected to achieve a price-to-earnings (P/E) ratio of 22.26 in 2025, decreasing to 9.23 by 2027, indicating improving profitability over time [5].

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Investment Rating - The investment rating for the company is "Buy" [4][9]. Core Insights - The company has launched the visionJet G3, which features significant upgrades in consumer orientation, including a fully upgraded avionics system, enhanced cabin comfort, and improved performance metrics such as maximum flight speed and payload capacity [1][4]. - The target customer base is high-net-worth individuals rather than professional pilots, focusing on smart and safe performance upgrades to address pain points during flights, which is expected to enhance customer acquisition and market penetration [1]. - The company is expanding its production capacity and improving its delivery structure, which is anticipated to lead to better order fulfillment and increased revenue from new product lines [1][4]. Financial Projections - Revenue is projected to grow from $1,068 million in 2023 to $1,902 million in 2027, with a compound annual growth rate (CAGR) of approximately 17.1% [3][8]. - Net profit is expected to increase from $91 million in 2023 to $237 million in 2027, reflecting a CAGR of about 22.8% [3][8]. - Earnings per share (EPS) is forecasted to rise from $0.59 in 2023 to $0.65 in 2027, with a decreasing price-to-earnings (P/E) ratio from 32.4 in 2023 to 12.4 in 2027, indicating potential valuation recovery [3][8].

证券研究报告·海外公司点评·旅游及消闲设施(HS) 百胜中国（09987.HK） 百胜中国 2025Q4 及全年业绩公告点评：质 地稳健的高股息龙头，维持推荐 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万美元） | 11,303 | 11,797 | 12,686 | 13,426 | 14,262 | | 同比(%) | 2.96 | 4.37 | 7.54 | 5.83 | 6.23 | | 归母净利润（百万美元） | 911.00 | 929.00 | 1,042.71 | 1,143.75 | 1,262.86 | | 同比(%) | 10.16 | 1.98 | 12.24 | 9.69 | 10.41 | | EPS-最新摊薄（美元/股） | 2.57 | 2.62 | 2.94 | 3.23 | 3.56 | | P/E（现价&最新摊薄） | 22.10 | 21.67 | 19.31 | 17.61 | ...

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p ...

Investment Rating - The report maintains a positive outlook on JD Health, indicating strong sales growth and a favorable investment environment [5][7]. Core Insights - JD Health is expected to maintain robust growth momentum in the second half of 2025, with revenue projected to increase year-on-year, driven by strong performance during the "Double 11" shopping festival and a surge in flu cases in December [5]. - The sales of pharmaceuticals and health products are particularly strong, with adjusted EBITDA expected to double due to margin expansion and operational leverage, offsetting investments in offline stores [5]. - The report highlights that JD Health's direct sales are anticipated to grow year-on-year in the second half of 2025, primarily driven by increased sales of pharmaceuticals and health products during the "Double 11" period [5][6]. Summary by Sections Company Overview - JD Health operates an online retail pharmacy business through self-operated and platform models, focusing on three core categories: pharmaceuticals (including prescription and OTC), health products, and medical devices [10]. Revenue Breakdown - Pharmaceuticals and health products account for 85.3% of revenue, while platform services, advertising, and other sources contribute 14.7% [11]. Market Position - As of February 4, 2026, JD Health's stock price is HKD 60.95, with a market capitalization of USD 26.24 billion and a consensus target price of HKD 76.85 [13].

Investment Rating - The report assigns a "Hold" rating for the company [6] Core Insights - The company is positioned as a leading player in the digital family office and AI investment community, focusing on integrating family office services with AI financial technology [7] - The family office business is expected to experience strong growth, with plans to increase the number of clients from 60 to 200 and assets under management (AUM) from $2.5 billion to over $10 billion by 2026 [7] - The report highlights the significant policy advantages in Hong Kong that support the family office sector, including tax incentives and regulatory flexibility [7] Financial Forecast - Revenue projections for the company are as follows: - 2024: HKD 202.40 million - 2025: HKD 189.70 million - 2026: HKD 257.40 million (growth of 35.69%) - 2027: HKD 332.60 million (growth of 29.22%) - 2028: HKD 438.85 million (growth of 31.95%) [2] - Net profit forecasts are: - 2024: HKD 99.90 million - 2025: HKD 136.80 million (growth of 36.94%) - 2026: HKD 362.17 million (growth of 164.74%) - 2027: HKD 421.81 million (growth of 16.47%) - 2028: HKD 474.51 million (growth of 12.49%) [2] - Earnings per share (EPS) estimates are: - 2024: HKD 0.07 - 2025: HKD 0.09 - 2026: HKD 0.17 - 2027: HKD 0.20 - 2028: HKD 0.23 [2] Company Overview - The company operates as a diversified financial group with a focus on family office services, traditional financial services, and digital finance [12] - It has a total share capital of 2.07 billion shares and a market capitalization of HKD 39.1 billion [3] - The company has experienced fluctuations in its stock price, with a 30-day average trading volume of 54.48 million shares [3] Business Segments - The main revenue sources for the company include: - Licensed financial services: 57.64% - Family office services: 28.12% [13] - The company has seen significant growth in its family office services, with revenue increasing nearly 3.3 times year-on-year [27]

Investment Rating - The report maintains a "Buy" rating for Yum China (09987.HK) [1] Core Insights - Yum China reported a 4% year-over-year increase in total revenue for the full year 2025, with a 9% increase in Q4 revenue, exceeding previous expectations [7] - The company achieved a net profit growth of 2% for the full year and 24% for Q4, attributed to automation, lean operations, and improved raw material costs [7] - The total number of stores reached 18,100 by the end of 2025, with a net addition of 1,706 stores throughout the year [7] - Same-store sales showed significant improvement, with a 1% increase for the full year and a 3% increase in Q4 [7] - The outlook for 2026 is positive, with plans to exceed 20,000 stores and a capital expenditure of $600-700 million [7] - The company plans to return $1.5 billion to shareholders in 2025, with a dividend yield of nearly 8% [7] - Earnings forecasts for 2026-2028 have been adjusted upwards, with projected net profits of $1.04 billion, $1.14 billion, and $1.26 billion respectively [7] Financial Summary - Total revenue projections for 2024 to 2028 are $11.30 billion, $11.80 billion, $12.69 billion, $13.43 billion, and $14.26 billion respectively, with year-over-year growth rates ranging from 2.96% to 7.54% [1] - Net profit projections for the same period are $911 million, $929 million, $1.04 billion, $1.14 billion, and $1.26 billion, with growth rates from 1.98% to 12.24% [1] - The latest diluted EPS estimates are $2.57, $2.62, $2.94, $3.23, and $3.56 for the years 2024 to 2028 [1] - The current P/E ratios are projected to decrease from 22.10 in 2024 to 15.94 in 2028 [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [4]. Core Insights - The company has signed a strategic research and development collaboration agreement with AstraZeneca, granting AstraZeneca exclusive global rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects. The company will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty on net sales [1][2]. - The collaboration marks an upgrade from single product licensing to platform licensing, reflecting AstraZeneca's strong recognition of the company's long-acting peptide and AI pharmaceutical technology platforms [1]. - The company is advancing its proprietary sustained-release drug delivery technology and AI drug discovery platform, which enhances patient compliance by allowing for monthly or longer dosing intervals [2]. Financial Summary - The company's projected revenues for 2025-2027 are estimated at 28.8 billion, 35.9 billion, and 32.5 billion CNY, respectively, with a compound annual growth rate (CAGR) of 24.62% in 2026 [3]. - The net profit attributable to the parent company is forecasted to be 5.34 billion, 7.87 billion, and 6.76 billion CNY for 2025-2027, with corresponding earnings per share (EPS) of 0.46, 0.68, and 0.59 CNY [3]. - The current market capitalization is approximately 112.23 billion HKD, with a total share count of 11,522 million [4].